The abstract is read at the publisher; the summary is JClub's.
In CPI-experienced advanced melanoma patients, simlukafusp alfa plus pembrolizumab increased circulating CD8+ T-cell and NK-cell subsets and expanded melanoma-specific CTLs in a subset, with 11 peptide–HLA specificities detected.
- Why it matters: After checkpoint inhibitor failure, it is unclear whether wild-type melanoma antigen–specific CD8+ CTLs persist and can still be functionally reactivated, limiting rational next-step immunotherapy design.
- What they did: In a subset of 33 patients from the BP41054 Phase I trial, peripheral blood was profiled at C1D1_pre and C2D8 using quantitative immunophenotyping and 28 peptide–HLA tetramers spanning 14 antigens, with CTL function tested by ex vivo peptide challenge and IFN-γ intracellular staining.
- The result: Antigen-specific CTLs showed IFN-γ responses with variable peptide and patient activity, but exhaustion marker co-expression persisted; exploratory analyses linked increased CTL diversity to longer median PFS, reported descriptively (3 patients per group).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.